Featured Research

from universities, journals, and other organizations

New Method For Detecting Nitroxyl Will Boost Cardiac Drug Research

Date:
August 3, 2009
Source:
Wake Forest University
Summary:
Scientists have developed a new research tool in the pursuit of heart medications based on the compound nitroxyl by identifying unique chemical markers for its presence in biological systems.

Wake Forest University scientists have developed a new research tool in the pursuit of heart medications based on the compound nitroxyl by identifying unique chemical markers for its presence in biological systems.

Nitroxyl, a cousin to the blood-vessel relaxing compound nitric oxide, has been shown in studies to strengthen canine heart beats, but research into its potential benefits for humans has been slowed by a lack of specific detection methods.

"I think this is a very powerful tool to help in the development of new drugs for congestive heart failure," said S. Bruce King, a professor of chemistry at Wake Forest who leads the team that conducted the research.

Researchers can generate nitroxyl from precursor chemicals under controlled conditions, but studying the molecule's activity in cells is difficult because its constituent elements—nitrogen, oxygen and hydrogen—react so readily with other molecules. King's research team used compounds that are not present in normal cell biology to produce a reaction that yields the identifying chemical markers.

King has been investigating nitrogen oxide compounds at Wake Forest since 1995. While scientists have established that the human body naturally produces nitric oxide, natural production of nitroxyl is suspected but has not been demonstrated. King said the new chemical markers could help answer that question, as well.

King's research team has received support from the National Institutes of Health, the National Science Foundation, the American Heart Association and the North Carolina Biotechnology Center.


Story Source:

The above story is based on materials provided by Wake Forest University. Note: Materials may be edited for content and length.


Journal Reference:

  1. Reisz et al. Reductive Phosphine-Mediated Ligation of Nitroxyl (HNO). Organic Letters, 2009; 11 (13): 2719 DOI: 10.1021/ol900914s

Cite This Page:

Wake Forest University. "New Method For Detecting Nitroxyl Will Boost Cardiac Drug Research." ScienceDaily. ScienceDaily, 3 August 2009. <www.sciencedaily.com/releases/2009/07/090706090319.htm>.
Wake Forest University. (2009, August 3). New Method For Detecting Nitroxyl Will Boost Cardiac Drug Research. ScienceDaily. Retrieved July 22, 2014 from www.sciencedaily.com/releases/2009/07/090706090319.htm
Wake Forest University. "New Method For Detecting Nitroxyl Will Boost Cardiac Drug Research." ScienceDaily. www.sciencedaily.com/releases/2009/07/090706090319.htm (accessed July 22, 2014).

Share This




More Health & Medicine News

Tuesday, July 22, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Courts Conflicted Over Healthcare Law

Courts Conflicted Over Healthcare Law

AP (July 22, 2014) Two federal appeals courts issued conflicting rulings Tuesday on the legality of the federally-run healthcare exchange that operates in 36 states. (July 22) Video provided by AP
Powered by NewsLook.com
Why Do People Believe We Only Use 10 Percent Of Our Brains?

Why Do People Believe We Only Use 10 Percent Of Our Brains?

Newsy (July 22, 2014) The new sci-fi thriller "Lucy" is making people question whether we really use all our brainpower. But, as scientists have insisted for years, we do. Video provided by Newsy
Powered by NewsLook.com
Scientists Find New Way To Make Human Platelets

Scientists Find New Way To Make Human Platelets

Newsy (July 22, 2014) Boston scientists have discovered a new way to create fully functioning human platelets using a bioreactor and human stem cells. Video provided by Newsy
Powered by NewsLook.com
Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins